Scilex Holding (SCLX) Share-based Compensation (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Share-based Compensation of $3.6 million for Q1 2026, up 9.51% year-over-year from $3.3 million in Q1 2025, and up 148.72% on a QoQ basis from -$7.4 million in Q4 2025.
Scilex Holding (SCLX) Share-based Compensation (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Share-based Compensation for 5 consecutive years, with $3.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 9.51% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $2.7 million (down 82.42% YoY), while the FY2025 annual figure was $2.4 million, down 84.7% from the prior year.
- Share-based Compensation came in at $3.6 million for Q1 2026 at Scilex Holding, up from -$7.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $4.8 million in Q4 2024, with the low at -$7.4 million in Q4 2025.
- Average Share-based Compensation over 5 years is $2.4 million, with a median of $3.5 million recorded in 2023.
- Across the five-year window, Share-based Compensation surged 201.92% in 2023 and plunged 255.03% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $1.3 million in 2022, then soared by 201.92% to $3.8 million in 2023, then gained by 27.02% to $4.8 million in 2024, then slumped by 255.03% to -$7.4 million in 2025, then surged by 148.72% to $3.6 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3.6 million, -$7.4 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 161.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 300.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 444.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 185.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 218.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 272.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 3.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.63 Mn |
| Mar 31, 2026 | 3.63 Mn |
| Dec 31, 2025 | -7.45 Mn |
| Dec 31, 2025 | -7.45 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 3.31 Mn |
| Mar 31, 2025 | 3.31 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Dec 31, 2023 | 3.78 Mn |
| Dec 31, 2023 | 3.78 Mn |